

Supplementary file : Characteristics of protocols submitted for review before (Period 1) and during Covid-19 (Period 2)

Attributes	All protocols		Period 1		Period 2	
	n	%	n	%	n	%
<b>Study type</b>						
KEMRI	169	85.4	67	39.6	102	60.4
Non KEMRI	29	14.5	14	48.3	15	51.7
<b>Review category</b>						
Expedited	36	18.2	7	8.6	29	24.8
Quick turn around	24	12.1	0	0	24	20.5
Full board	138	69.7	74	91.4	64	54.7
<b>Study design</b>						
Case control	23	11.7	12	15.2	11	9.4
Cohort	23	11.7	12	15.2	11	9.4
Desktop-based review	9	9.6	4	5.1	5	4.3
Cross-sectional	75	38.3	24	30.4	51	43.6
Clinical trial	31	15.7	15	19.0	16	13.7
Laboratory studies	35	17.9	12	15.2	23	19.7
<b>Program area</b>						
Non communicable diseases	20	10.2	9	11.4	11	9.4
Natural products research and drug development	5	2.6	1	1.3	4	3.4
Infectious and parasitic diseases	89	45.4	35	44.3	54	46.2
Biotechnology	14	7.1	6	7.6	8	6.8
Sexual reproductive and child health	19	9.7	10	12.7	9	7.7
Public health and health systems research	43	21.9	14	17.7	29	24.8
One health	6	3.1	4	5.1	2	1.7
<b>Approval turnaround time (median/IQR)</b>	79	61-106.7	89.5	74.5-123.2	67	54.2-98
<b>Number of revisions (median/IQR)</b>	1	1-1	1	1-1	1	1-2